VTE Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about VTE clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism

Quality of Life (QOL)Exercise TherapyAnxiety Depression+7 more
Insel Gruppe AG, University Hospital Bern160 enrolled5 locationsNCT07143539
Recruiting

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

Lung Cancer (Diagnosis)Venous Thromboembolism (VTE)Deep Vein Thrombosis (DVT)
The First Hospital of Jilin University900 enrolled1 locationNCT07439991
Recruiting
Not Applicable

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

LymphomaLeukemiaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma+4 more
Medical University of Gdansk100 enrolled1 locationNCT07270263
Recruiting

Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)Venous Thromboembolism (VTE)
University Of Perugia500 enrolled1 locationNCT07288632
Recruiting

Heat Shock Protein 47 in Thrombosis

Venous Thromboembolism (VTE)Stroke (in Patients With Atrial Fibrillation)Acute Myocardial Infarction With ST Segment Elevation
University of Aarhus340 enrolled2 locationsNCT06731673
Recruiting
Not Applicable

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

Atrial Fibrillation (AF)VTE
McMaster University920 enrolled14 locationsNCT06957366